
CORRIGENDUM

Alzheimer antibody drugs show questionable potential

Sara Reardon

Nature Reviews Drug Discovery 14, 591–592 (2015)

The description of the reanalysis of the EXPEDITION 1, 2 and EXT trials of solanezumab on p592 was inaccurate, and it is the last patient visit for the EXPEDITION 3 trial that is due in October 2016, not the final results. Changes have been made to correct these errors in the online version of the article.